Oncolytic effect of Midkine promoter–based conditionally replicating adenoviruses expressing EGFR siRNA in head and neck squamous cancer cell line T891. Issue 3 (3rd February 2020)

• Record Type: Journal Article
• Authors: Uehara, Natsumi; Otsuki, Naoki; Kubo, Mie; Kitamoto, Junko; Kojima, Yasutaka; Teshima, Masanori; Shinomiya, Hirotaka; Shirakawa, Toshiro; Nibu, Ken‐ichi
• Is Part Of: Cancer reports. Volume 3:Issue 3(2020)
• Page Start: n/a
• Page End: n/a
• Publication Date: 2020-02-03
• Subjects: conditionally replicative adenovirus -- EGFR -- head and neck cancer -- Midkine -- siRNA; Cancer -- Periodicals; 616.994005
• DOI: 10.1002/cnr2.1231
• Languages: English
• ISSNs: 2573-8348

Abstract

Abstract: Background: Epidermal growth factor receptor (EGFR) is overexpressed in head and neck squamous cell carcinomas (HNSCCs). Midkine expression is restricted in adult tissues but is increased in several malignant tumors, including HNSCCs. Aim: Here, we evaluated the antitumor effect of Midkine promoter–based conditionally replicative adenovirus expressing siRNA against EGFR for targeting HNSCCs expressing Midkine. Methods and results: A conditionally replicative adenovirus vector controlled by the Midkine promoter, Ad‐MK‐siEGFR, was generated by integrating gene‐expressing siRNA against EGFR. Antitumor effect of Ad‐MK‐siEGFR was tested in vitro using established HNSCC cell line, T891 with strong Midkine expression. Expression of EGFR in T891 infected with Ad‐MK‐siEGFR was significantly lower than that of T891 infected with control. Cytotoxicity assays showed significant growth suppression of Ad‐MK‐siEGFR in T891 cells. Conclusions: This study demonstrated the possibility of oncolytic therapy using the Midkine promoter–based conditional replication‐selective adenovirus containing siRNA against EGFR in HNSCC cell line T891. Further validation of the findings in more cell lines and in vivo should be performed to clarify the potential clinical application.